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Abstract
Soon after identification of the platelet membrane glycoprotein (GP) IIb/IIIa, it has become  
a target of antiplatelet therapy. There are 3 intravenous GP IIb/IIIa receptor inhibitors, namely 
— eptifibatide, tirofiban and abciximab, used in the contemporary clinical practice, particular-
ly in patients with acute coronary syndrome undergoing percutaneous coronary intervention 
(PCI). The aim of the current review is to summarize available knowledge concerning off-target 
effects of GP IIb/IIIa receptor inhibitors. All 3 drugs have similar antithrombotic properties, but 
differ with respect to pharmacodynamics, pharmacokinetics and off-target effects. Eptifibatide 
and tirofiban are highly specific GP IIb/IIIa receptor inhibitors, while abciximab is unselec-
tive and cross-reacts with integrin avb3 — a vitronectin receptor and leukocyte-associated 
integrin Mac-1. As a result of these interactions, abciximab seems to reduce the development 
of clinical restenosis, decrease infarct size, inhibit adhesion of monocytes to medical steel and 
modulate the inflammatory response. Intracoronary administration of abciximab provides 
higher drug concentration in the target area, increasing dose-dependent interactions with other 
integrins. Off-target effects of small molecule GP IIb/IIIa receptor inhibitors (i.e. eptifibatide 
and tirofiban) are predominantly connected with their suppressive influence on the inflam-
matory response. All in all, although GP IIb/IIIa receptor inhibitors are not recommended as  
a routine therapy during PCI, their antiplatelet properties and potential off-target effects may be  
beneficial in certain subsets of patients. (Cardiol J 2014; 21, 5: 458–464)
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Introduction
The identification of the platelet membrane 
glycoprotein (GP) IIb/IIIa receptor was a milestone 
in the understanding of thrombus formation. Be-
cause of its key role in platelet aggregation, it has 
quickly become a target of antiplatelet therapy. In 
1994, results of the EPIC trial demonstrated the 
efficacy of GP IIb/IIIa receptor blockade in reducing 
thrombotic complications in patients undergoing 
high risk percutaneous coronary interventions 
(PCIs) [1]. Within the next 5 years 3 intravenous 
GP IIb/IIIa receptor inhibitors (GPIs) were appro-
ved for clinical practice, particularly in patients 
treated with PCI due to acute coronary syndrome 
(ACS) [2–6]. These three drugs possess similar 
antiplatelet properties, but differ with respect to 
pharmacodynamics, pharmacokinetics and off-target 
effects (Table 1). According to the recent European 
guidelines on ST-segment elevation myo cardial 
infarction, GPIs should be considered for bailout 
therapy if there is an angiographic evidence of massi-
ve thrombus, in case of slow flow or no-reflow or if 
a thrombotic complication occurs (class of recom-
mendation IIa, level of evidence C) [6].
The aim of the current review is to summarize 
available knowledge concerning off-target effects 
of GPI.
A search covering the period from January 
1993 to November 2013 was conducted by two 
independent investigators using MEDLINE, CEN-
TRAL and Google Scholar databases. Proceedings 
from the Scientific Sessions of the American Col-
lege of Cardiology (http://www.acc.org), American 
Heart Association (http://www.heart.org), the Eu-
ropean Society of Cardiology (http://www.escardio.
org), Transcatheter Cardiovascular Therapeutics 
(http://www.tctmd.com), and EuroPCR (http://www.
europcr.com) were also considered. The following 
keywords were applied: “abciximab”, “eptifibatide”, 
“tirofiban”, “GP IIb/IIIa receptor inhibitor”, “off-
-target effects”. References of studies retrieved 
were searched manually for additional studies and 
reviews. No language restrictions were applied.
Structure and role of the  
GP IIb/IIIa receptor
It is well known that platelet aggregation and 
thrombus formation play a pivotal role in ACS 
[7–9]. The rupture of atherosclerotic plaque initia-
tes platelet adhesion, which is followed by platelet 
activation, including conformational changes in 
platelet structure, such as activation of the GP IIb/ 
/IIIa receptors, and finally stimulation of platelet 
aggregation. The GP IIb/IIIa receptor belongs to 
the integrin family of adhesion molecules, compo-
sed of a and b subunits (Fig. 1) [10]. After platelet 
activation, the GP IIb/IIIa receptor develops a high 
affinity for fibrinogen. The fibrinogen molecule 
has binding sites at both ends, allowing bridging 
between neighboring platelets, thus leading to 
thrombus formation [11]. GPI prevents the binding 
of fibrinogen to the adjacent GP IIb/IIIa receptors 
[12]. By this mechanism, the final common pathway 
of platelet aggregation is blocked. There are 3 in-
travenous GPIs that are used in everyday practice, 
namely abciximab (large molecule), and 2 small 
molecule agents — eptifibatide and tirofiban.
Abciximab
Abciximab is a part-murine, part-human chi-
meric Fab fragment of the monoclonal 7E3 IgG3 
Table 1. Characteristics of intravenous glycoprotein IIb/IIIa inhibitors.
Abciximab Eptifibatide Tirofiban
Type Monoclonal anti-
body fragment
Cyclic heptapeptide Non-peptide tyrosine  
derivative
Inhibition Noncompetitive Competitive Competitive
Platelet affinity High Low Intermediate
Standard dosage:
Bolus 0.25 mg/kg 180 μg/kg –
Infusion 0.125 μg/kg/min 2 μg/kg/min 0.4 μg/kg/min over 30 min, 
next 0.1 μg/kg/min
Plasma half-life < 10 min 2.5 h 1.5 h
Selectivity Non-selective Selective Selective
Route of elimination Spleen Renal Renal and biliary
Recovery of platelet function 24–48 h 4 h 4 h
Reversibility with platelets infusion Yes No No
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antibody against the GP IIb/IIIa receptor. Its struc-
ture is based on a murine monoclonal antibody, first 
described by Coller at al. [13, 14]. Abciximab is 
a competitive, reversible GP IIb/IIIa receptor inhibi-
tor, which binds to platelets with very high affinity. 
It is characterized by a short plasma half-life due to 
its rapid binding to the platelet receptor. The binding 
site of abciximab is located on the b3 chain of the 
GP IIb/IIIa receptor [15]. High local concentration 
of abciximab obtainable with intracoronary admini-
stration results in dissolution of existing platelet-
-rich thrombi and extensive dispersion of platelet 
aggregates, thus reducing distal microembolization 
[16–18]. The inhibition of platelet-induced thrombin 
generation observed with high concentration of 
abciximab is associated with a decreased release 
of platelet granules containing inhibitors of fibri-
nolysis such as plasminogen activator inhibitor-1 
and a2-anti-plasmin [19]. The increased porosity of 
thrombus caused by c7E3 Fab allows penetration of 
endogenous fibrinolytic agents into the clot, thereby 
promoting spontaneous thrombolysis [18].
In contrast to small-molecule GPIs, abciximab 
is a non-selective GP IIb/IIIa receptor antagonist. 
Since the b3 subunit is also present in integrin 
avb3, abciximab also binds to this cellular vitronec-
tin receptor expressed on endothelial and smooth 
muscle cells, monocytes, polymorphonuclear leu-
kocytes, and T lymphocytes [19–21]. Abciximab 
also cross-reacts with the leukocyte-associated in-
tegrin Mac-1 (aMb2). Intracoronary administration 
producing high local concentration of abciximab 
may also enhance the non-GP IIb/IIIa properties of 
this agent that are mainly based on complex anti-
inflammatory interactions, with off-target effects 
of abciximab being their consequence.
The endothelial integrin avb3 can bind to 
several molecules such as fibrinogen, vitronectin, 
thrombospondin and prothrombin. It also causes 
endothelial adhesion of activated platelets and 
entrapment of leukocytes in the platelet-fibrin 
mesh. It is upregulated in case of ischemia, pre-
dominantly in small arterioles. As an antagonist of 
integrin avb3, abciximab may influence restenosis, 
a process of vessel re-narrowing after initially 
successful PCI. Detailed avb3-mediated effects 
of abciximab, potentially preventing restenosis, 
include inhibition of smooth muscle cell (SMC) mi-
gration and proliferation, thrombin generation and 
clot retraction. SMC migration and proliferation 
initiate the process of restenosis [22]. In a study by 
Baron et al. [23], abciximab inhibited adhesion and 
migration of human SMC, while Stouffer et al. [24] 
described hindering influence of abciximab on SMC 
proliferation in a baboon model. Furthermore, an in 
vitro study showed abciximab to be a potent inhibi-
tor of human coronary artery SMC migration and 
invasion [25]. Therefore, avb3-mediated effects of 
abciximab on the development of restenosis may 
explain the lower incidence of need for long-term 
recurrent coronary interventions in the EPIC trial 
[1]. In addition, the EPISTENT and ISAR-SWEET 
trials suggested a reduction in clinical restenosis 
in favor of abciximab in diabetic patients [26, 27]. 
Similar results were observed in a large Danish 
single-center registry [28]. In a meta-analysis 
by Wu et al. [29], a decreased 1-year target le-
sion revascularization risk was the only benefit 
from abciximab therapy. However, these promis-
ing long-term results were not confirmed in the 
ERASER, EPILOG and CAPTURE trials [2, 3, 30]. 
Moreover, the beneficial effects on restenosis from 
abciximab therapy present in diabetic patients re-
ceiving coronary bare metal stents were absent in 
diabetic patients undergoing elective drug-eluting 
stents implantation [31]. In the STRATEGY trial, 
the conjunction of tirofiban plus sirolimus-eluting 
stent was confronted with abciximab plus bare 
metal stent. The significantly lower occurrence of 
restenosis and the need for target vessel revascu-
larization observed with tirofiban plus sirolimus-
eluting stent [32] suggest that reduction in clinical 
restenosis is less pronounced in patients treated 
with abciximab than in those receiving drug-eluting 
stents. The addition of tirofiban to sirolimus-eluting 
stent seemed to have no influence on restenosis. 
Figure 1. Glycoprotein IIb/IIIa receptor.
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This was further confirmed in the ADVANCE trial, 
where the administration of high-dose bolus of 
tirofiban had no significant effect on target vessel 
revascularization [33].
Referring to an accumulating body of evidence 
on the influence of abciximab on restenosis, Kim 
et al. [34, 35] took another step ahead and tested 
abciximab-coated stents in the setting of stable 
coronary artery disease, as well as in acute myo-
cardial infarction (AMI), proving abciximab-coated 
stents to be safe and effective in the prevention 
of coronary restenosis. Unfortunately, in a 2-year 
follow-up, abciximab-coated stents did not show 
superiority over bare metal stents [36]. Hong et 
al. [37] compared the anti-inflammatory effects of 
abciximab-coated stents, sirolimus-eluting stents, 
and paclitaxel-eluting stents in an animal coronary 
restenosis model. The results were comparable 
with respect to inhibition of inflammatory cell in-
filtration and neointimal hyperplasia in abciximab-
-coated stents and other drug-eluting stents.
Sakuma et al. [38] compared the effect of the 
combined blockade of the GP IIb/IIIa receptor and 
integrin avb3 with the blockade of GP IIb/IIIa 
receptor alone, using a highly specific inhibitor 
— tirofiban, relating the results to a control group 
receiving saline. They found that out of these 3, 
simultaneous inhibition of GP IIb/IIIa and integrin 
avb3 cause a marked reduction in infarct size, in 
a model of acute coronary thrombosis and primary 
PCI, which is associated with reduced myocardial 
microthrombi and inflammation, as well as im-
proved myocardial blood flow and regional function 
[38]. Abciximab was not used in the study, but as 
far as we know, abciximab inhibits both — the GP 
IIb/IIIa receptor and integrin avb3, so we may as-
sume that the effect would be similar.
The leukocyte b2 integrin Mac-1 is a pivotal 
adhesion molecule, involved in the interaction of 
neutrophils and monocytes with the microvascu-
lature, limiting reperfusion in AMI [39–42]. In 
a study by Neumann et al. [43], increased platelet-
-leukocyte interaction in patients with AMI was 
observed. Importantly, the authors demonstrated 
that binding of activated platelets induces the 
release of interleukin-1b, interleukin-8, and mo-
nocyte chemoattractant protein-1 in leukocytes. 
The study findings suggest that leukocyte-platelet 
adhesion contributes to the regulation of inflam-
matory responses in AMI. In another research, 
Neumann et al. [44] demonstrated that abciximab 
reduces Mac-1 surface expression and platelet-
-leukocyte interaction, by decreasing the platelet 
mass in platelet-monocyte aggregates.
According to Schuler et al. [45], the monocyte 
integrin receptor Mac-1 is a central mediator of 
monocyte adhesion to medical steel, for example 
metal stents. Since cell adhesion could be blocked 
by anti-Mac-1-antibodies, the cross-reacting 
anti-GP IIb/IIIa antibody fragment — abciximab — 
may potentially inhibit monocyte adhesion to stents.
Schwarz et al. [46] found that abciximab not 
only binds to the leukocyte integrin Mac-1, but 
also inhibits binding of several distinct ligands and 
thereby may modulate inflammation, cell prolifera-
tion, and coagulation. The binding of fibrinogen, the 
inactivated complement factor 3b and the coagula-
tion factor X to Mac-1 was inhibited by abciximab in 
vitro. As a functional consequence, the conversion 
of factor X to factor Xa mediated by Mac-1 was 
impaired by abciximab. The adhesion of monocytic 
cell line to immobilized intercellular adhesion mole-
cule 1 and to fibrinogen, ligands abundant in the 
injured vessel wall, was reduced significantly by 
abciximab [47]. Fibrinogen-mediated cell aggrega-
tion was also impaired. Overall, the inhibition of 
Mac-1 can provide additional clinical benefits of 
abciximab beyond the well-described blockade of 
GP IIb/IIIa.
Inflammation plays an important role in the 
progression of atherosclerosis [48]. Systemic 
markers of inflammation are increased in patients 
with ACS and usually rise within 24 h to 48 h after 
PCI [49, 50]. Cross-reactions of abciximab with 
integrins avb3 and Mac-1 are assumed to decrease 
the endothelial inflammatory reaction. In their 
study, Lincoff et al. [51] measured the concentra-
tion of C-reactive protein (CRP), interleukin-6 and 
tumor necrosis factor a before and 24–48 h after 
PCI. They observed, that in patients receiving peri-
procedural abciximab, the magnitude of rise of the 
measured inflammatory markers was diminished, 
compared with patients receiving placebo [51].
Recently the topic of intracoronary use of ab-
ciximab has been extensively discussed in the lite-
rature [52–56]. This administration route seems to 
provide a much higher concentration of abciximab 
in the target area and possibly allow direct influence 
not only on the platelet GP IIb/IIIa receptor, but 
also on vitronectin and Mac-1 receptors, enhancing 
dose-dependent off-target effects of abciximab. 
Two independent small randomized trials showed 
intracoronary administration of abciximab to be 
associated with improved myocardial perfusion 
and smaller infarct size [57, 58].
A bolus of abciximab is usually administered 
through the guiding catheter into the infarct-
-related artery. This method does not assure an 
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optimal effect of abciximab, with the rapid wash 
out by the coronary flow. Prati et al. [59] tested 
the effectiveness of local abciximab delivery to the 
site of IC thrombus vs. IC bolus infusion in patients 
with ACS undergoing PCI. For local IC delivery 
of abciximab a dedicated perfusion catheter was 
applied. This catheter enables local drug delivery 
to reach approximately a 500-fold higher drug 
concentration vs. systemic delivery. Significantly 
lower rates of procedure-related AMI and major 
adverse cardiac events at 1 year were observed in 
the local intracoronary infusion group. These re-
sults strongly suggest that the use of the dedicated 
perfusion catheter leads to higher concentrations 
of abciximab within the thrombus, allowing for an 
additional antiplatelet, antithrombotic, and anti-
-inflammatory effect [59].
Further efforts should be undertaken to define 
the benefits of super-selective local delivery of 
abciximab.
Small molecular weight GPIs:  
Eptifibatide and tirofiban
Eptifibatide is a cyclic heptapeptide modeled 
on the structure of barbourin — a disintegrin 
that contains a KGD aminoacid sequence, which 
provides this molecule with high specificity for 
binding to the GP IIb/IIIa receptor. Eptifibatide 
acts specifically on the aIIb chain of the GP IIb/ 
/IIIa receptor, which is a RGD binding site. It is 
a selective molecule for the GP IIb/IIIa recep-
tor with very rapid association and dissociation 
kinetics concerning this receptor, while it shows 
no reactivity with other integrins. Eptifibatide is 
eliminated by the kidneys, with the most of it ex-
creted as the unchanged drug in the urine.
Tirofiban is a non-peptide tyrosine derivative. 
Like eptifibatide, it is an antagonist against the 
RGD binding site on the aIIb chain of the GP IIb/ 
/IIIa receptor [60]. It is also highly specific for the 
GP IIb/IIIa receptor and does not interact with 
other integrins. Tirofiban’s affinity for the GP IIb/ 
/IIIa receptor is intermediate between abciximab 
and epitfibatide. It has also very rapid association 
and dissociation with the GP IIb/IIIa receptor. Tiro-
fiban is removed by both renal and biliary excretion.
Both tirofiban and eptifibatide may exert 
anti-inflammatory effects. In a study by Azar et al. 
[61], in high risk patients undergoing PCI, tirofiban 
significantly suppressed the rise of high sensitivity 
CRP. In a paper by Walters et al. [62], the combina-
tion of high dose tirofiban with enoxaparin resulted 
in an attenuated inflammatory response compared 
with the combination of high dose tirofiban with 
unfractionated heparin. Ercan et al. [63] explain the 
anti-inflammatory effect of tirofiban with platelet 
inhibition, since products of activated platelets may 
aid neutrophil accumulation and enhance inflamma-
tion. Activated leukocytes and platelets mutually 
potentiate each others’ effects. Tirofiban strongly 
inhibits the platelet aggregation. The decreased 
platelet aggregation can suppress the inflammatory 
proteins, chemokines, and the expression of adhe-
sion molecules. In their study, CRP elevation was 
attenuated in patients with non-ST segment eleva-
tion myocardial infarction (NSTEMI) treated with 
tirofiban infusion. Ueland et al. [64] confirmed the 
potential of eptifibatide as anti-inflammatory drug 
able to down-regulate platelet-mediated inflamma-
tion. On the other hand, Mazaev et al. [65] failed to 
find any anti-inflammatory effects of eptifibatide in 
patients with unstable angina and NSTEMI.
Summary
All the 3 agents discussed are effective inhibitors 
of the GP IIb/IIIa receptor. However, the exact bind-
ing site of each agent is different, causing potentially 
different functional responses in platelets. In addition, 
these agents have different specificities for other in-
tegrins. Tirofiban and eptifibatide have been designed 
to inhibit the platelet GP IIb/IIIa receptor without 
cross-reacting with other integrins. In contrast, ab-
ciximab is non-specific, because it also blocks integrin 
avb3 and leukocyte-associated integrin Mac-1. As a 
result of these interactions, some of the clinical ef-
fects of abciximab, such as anti-inflammatory effects, 
reduction of clinical restenosis and infarct size, go 
beyond the consequences of its plain binding to the 
GP IIb/IIIa receptor. All in all, although GPIs are not 
recommended as a routine therapy during PCI, their 
antiplatelet properties and potential off-target effects 
may be beneficial in certain subsets of patients.
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